COMMUNIQUÉS West-GlobeNewswire

Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics

09/04/2024 - 07:15

Allschwil, Switzerland, April 09, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal [...]

Stifel Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 12.00

09/04/2024 - 07:00

EINDHOVEN, the Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people [...]

OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024

09/04/2024 - 01:00

LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye [...]

Opthea Appoints John Han, PharmD, as VP Medical Affairs

09/04/2024 - 00:42

Brings extensive experience in retinal and ophthalmology diseases MELBOURNE, Australia and PRINCETON, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage [...]

Smith+Nephew signs exclusive distribution agreement to provide unique NAVBIT SPRINT™ solution in Australia

09/04/2024 - 00:00

Compact, single-use, and simple-to-use technology offers surgeons a fast, reliable navigation solution for hip arthroplasty Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announced an agreement [...]

Premier Health Announces the Appointment of Bruno Morel as its New CTO

08/04/2024 - 23:30

MONTRÉAL, April 08, 2024 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “ Corporation ” or “ Premier Health ”), a leading Canadian Health tech company, announces the appointment of Bruno Morel as [...]

Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing

08/04/2024 - 22:48

WARRINGTON, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), today announced that on April 2, 2024 the Company entered into an asset purchase agreement [...]

Onco360 Has Been Selected as the Sole National Specialty Pharmacy Partner for Voydeya® (danicopan)

08/04/2024 - 22:35

LOUISVILLE, Ky., April 08, 2024 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by Alexion Pharmaceuticals for Voydeya ® (Danicopan) [...]

Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024

08/04/2024 - 22:30

VIP236 demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metastatic solid tumors VIP943 pharmacokinetic (PK) data shows very [...]

Cellectis présentera deux posters sur un nouveau procédé d’édition par TALEN® pour la correction et l’insertion de gènes dans les cellules souches et progénitrices hématopoïétiques (HSPCs) à l’ASGCT

08/04/2024 - 22:30

NEW YORK, 08 avr. 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome TALEN ® pour développer [...]

Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting

08/04/2024 - 22:30

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving [...]

Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference

08/04/2024 - 22:30

SAN FRANCISCO, April 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]

Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform

08/04/2024 - 22:30

Novel camptothecin-peptide conjugates are well tolerated and associated with significant tumor regression in colorectal cancer and triple-negative breast cancer xenograft models SORT1 gene silencing results in drastic [...]

Theratechnologies présente des données précliniques au congrès 2024 de l’AACR qui met en évidence la polyvalence et la flexibilité de la plateforme technologique d’oncologie SORT1+(MC)

08/04/2024 - 22:30

Les nouveaux conjugués camptothécine-peptide sont bien tolérés et associés à une régression tumorale marquée dans les modèles de xénogreffe de cancer colorectal et de cancer du sein triple négatif L’inactivation du gène [...]

iCAD’s ProFound AI Suite Uncovers Hidden Heart Disease Risk According to New Data Presented at American College of Cardiology Meeting

08/04/2024 - 22:29

Study confirms iCAD’s Breast Arterial Calcification AI Algorithm successfully detects calcification of breast vessels, an indicator of cardiovascular disease, from mammograms NASHUA, N.H., April 08, 2024 (GLOBE NEWSWIRE [...]

IBEX Completes Sale of the Company

08/04/2024 - 22:10

MONTRÉAL, April 08, 2024 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) announces that it has completed the sale of the company by amalgamating with 15720273 Canada Inc., a newly [...]

CoreRx, Inc. Completes Acquisition of Societal CDMO, Inc.

08/04/2024 - 22:05

CLEARWATER, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- CoreRx, Inc. (“CoreRx”) today announced that it has completed its acquisition of Societal CDMO, Inc. (“Societal CDMO”) (Nasdaq: SCTL), a contract development and [...]

Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting

08/04/2024 - 22:05

PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and [...]

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights

08/04/2024 - 22:05

BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells [...]